{"analyses":[{"ciLowerLimit":"0.6409","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.9963","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0462","paramType":"Hazard Ratio (HR)","paramValue":"0.799","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.5568","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.2910","groupIds":["OG002","OG003"],"nonInferiorityComment":"The china cohort was not powered for superiority","nonInferiorityType":"OTHER","pValue":"0.4416","paramType":"Hazard Ratio (HR)","paramValue":"0.848","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"166"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"44"}]}],"title":"Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"17"}]}],"title":"Still in survival follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]}],"title":"Terminated prior to death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"65"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of randomisation until death from any cause and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy","groups":[{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG000","title":"Osimertinib 80 mg (Global Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG001","title":"SoC EGFR-TKI (Global Cohort)"},{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG002","title":"Osimertinib 80 mg (China Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG003","title":"SoC EGFR-TKI (China Cohort)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis set (FAS) and China-only FAS. FAS included all randomized participants prior to the end of global recruitment. The China-only FAS included all China participants randomized in mainland-China as part of the global study and all additional China participants recruited in mainland China after global recruitment was completed.","reportingStatus":"POSTED","timeFrame":"From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks (approximately 29 months)","title":"Overall Survival (OS)- Number of Participants With an Event","type":"SECONDARY","unitOfMeasure":"Participants"}